Oppenheimer raised the firm’s price target on Prothena (PRTA) to $62 from $58 and keeps an Outperform rating on the shares. The firm sees a uniquely favorable risk/reward setup for investors ahead of the Phase 3 AFFIRMAL readout for birtamimab in AL amyloidosis expected in the first half of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: